Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

268
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
268
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

415
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
415
Bacterial Phylum Spirochaetes01:30

Bacterial Phylum Spirochaetes

548
Spirochetes, unique bacteria in the phylum Spirochaetes, are gram-negative, motile, tightly coiled, slender, and flexible. They inhabit aquatic sediments and animals, with some causing diseases like syphilis. Spirochetes are classified into eight genera based on habitat, pathogenicity, phylogeny, and characteristics.Their distinctive motility arises from endoflagella, located within the cell’s periplasm. These endoflagella anchor at the cell poles and extend along the cell length, encased...
548
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

1.2K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.2K
Bacterial Phylum Actinobacteria01:30

Bacterial Phylum Actinobacteria

582
Coryneform bacteria are gram-positive, aerobic, nonmotile rods that exhibit irregular, club-shaped, or V-shaped arrangements. Their V-shape results from snapping division, where the inner cell wall layer forms the cross-wall, while the outer layer remains intact until it ruptures on one side, causing the daughter cells to bend away.The primary genera are Corynebacterium and Arthrobacter. Corynebacterium includes diverse species, ranging from saprophytes to pathogens like Corynebacterium...
582
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

2.6K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence-Based Frameworks Increase Engagement in Serious Illness Communication Conversations for Patients With Cirrhosis.

The American journal of hospice & palliative care·2026
Same author

Evaluating and monitoring liver disease severity in glycogen storage disease type IX: Performance of novel and established clinical scores.

Genetics in medicine open·2026
Same author

C no more: a prospective single-arm study to evaluate the effectiveness of a nurse and peer-led mobile model of hepatitis C testing and treatment at community corrections offices.

Health & justice·2026
Same author

Leveraging an Electronic Consultation Program for a High-Volume Hepatology Clinic.

Clinical and translational gastroenterology·2026
Same author

Reflex Testing for Hepatitis D Infection: A Unique Opportunity to Reduce Hepatitis D-Related Chronic Liver Disease Deaths in Australia.

The Medical journal of Australia·2026
Same author

The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus.

Hepatology communications·2026

Related Experiment Video

Updated: Jan 10, 2026

Bacterial Phylum Spirochaetes
01:30

Bacterial Phylum Spirochaetes

Published on: June 12, 2025

548

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose

Alexander J Thompson1, Jacques Fellay, Keyur Patel

  • 1Duke Clinical Research Institute, Durham, North Carolina 27715, USA.

Gastroenterology
|June 16, 2010
PubMed
Summary

Two ITPA gene variants protect against ribavirin-induced hemolytic anemia in chronic hepatitis C patients. These genetic variations reduce the need for ribavirin dose reduction during treatment.

More Related Videos

Development of Antibiotic Resistance
01:30

Development of Antibiotic Resistance

Published on: June 12, 2025

1.2K
Bacterial Phylum Actinobacteria
01:30

Bacterial Phylum Actinobacteria

Published on: June 6, 2025

582

Related Experiment Videos

Last Updated: Jan 10, 2026

Bacterial Phylum Spirochaetes
01:30

Bacterial Phylum Spirochaetes

Published on: June 12, 2025

548
Development of Antibiotic Resistance
01:30

Development of Antibiotic Resistance

Published on: June 12, 2025

1.2K
Bacterial Phylum Actinobacteria
01:30

Bacterial Phylum Actinobacteria

Published on: June 6, 2025

582

Area of Science:

  • Pharmacogenomics
  • Hepatology
  • Internal Medicine

Background:

  • Chronic hepatitis C treatment often involves ribavirin (RBV).
  • RBV can cause hemolytic anemia, a common side effect impacting treatment adherence.
  • ITPA gene variants are known to cause inosine triphosphatase (ITPase) deficiency, potentially affecting RBV metabolism.

Purpose of the Study:

  • To replicate the protective effect of ITPA variants against RBV-induced hemolytic anemia in an independent cohort.
  • To investigate the long-term impact of these ITPA variants on anemia and RBV dosing throughout hepatitis C treatment.

Main Methods:

  • Genotyping of two functional ITPA variants (rs1127354 and rs7270101) in 318 chronic hepatitis C patients.
  • Association analysis of ITPA variants with hemoglobin reduction at week 4.
  • Defining an ITPase deficiency variable combining both variants.
  • Evaluating the impact of ITPA variants on hemoglobin levels and RBV dose reduction over 48 weeks.

Main Results:

  • Both ITPA variants (rs1127354 and rs7270101) were strongly associated with reduced hemoglobin levels at week 4.
  • The combined ITPase deficiency variable showed a significant protective effect against Hb reduction (P = 2.4 × 10(-18)).
  • ITPA variants were associated with lower rates of anemia and reduced need for RBV dose reduction over 48 weeks (HR, 0.52; P = .0037).

Conclusions:

  • ITPA gene polymorphisms causing ITPase deficiency are strongly associated with protection against RBV-induced hemolytic anemia.
  • These variants significantly decrease the likelihood of requiring RBV dose reduction during chronic hepatitis C therapy.